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Abstract: In neuronal cells, tau is a microtubule-associated protein placed in axons and alpha synuclein
is enriched at presynaptic terminals. They display a propensity to form pathologic aggregates, which
are considered the underlying cause of Alzheimer’s and Parkinson’s diseases. Their functional
impairment induces loss of axonal transport, synaptic and mitochondrial disarray, leading to a “dying
back” pattern of degeneration, which starts at the periphery of cells. In addition, pathologic spreading
of alpha-synuclein from the peripheral nervous system to the brain through anatomical connectivity
has been demonstrated for Parkinson’s disease. Thus, examination of the extent and types of tau
and alpha-synuclein in peripheral tissues and their relation to brain neurodegenerative diseases is of
relevance since it may provide insights into patterns of protein aggregation and neurodegeneration.
Moreover, peripheral nervous tissues are easily accessible in-vivo and can play a relevant role in the
early diagnosis of these conditions. Up-to-date investigations of tau species in peripheral tissues
are scant and have mainly been restricted to rodents, whereas, more evidence is available on alpha
synuclein in peripheral tissues. Here we aim to review the literature on the functional role of tau
and alpha synuclein in physiological conditions and disease at the axonal level, their distribution
in peripheral tissues, and discuss possible commonalities/diversities as well as their interaction
in proteinopathies.
Keywords: tau; Big tau; alpha-synuclein; intrinsically disordered proteins; peripheral nervous
system; neurodegenerative disorders; proteinopathies; Alzheimer’s disease; Parkinson’s disease;
axonal degeneration
1. Introduction
The most common human neurodegenerative affections are Alzheimer’s disease (AD) and
Parkinson’s disease (PD), which respectively represent the first and second neurodegenerative disease
in the elderly [1]. AD is primarily a cognitive disorder, characterized by the presence of abundant
intraneuronal inclusions of assembled tau protein and extracellular amyloid plaques of Aβpeptides, and
it is classified as a tauopathy. Whereas PD is prevalently a movement disorder, which is characterized
by a single kind of intracellular amyloid assemblies, named Lewy inclusions, composed of alpha
synuclein (αSyn) protein [2]. Most cases of these pathologies are sporadic, but a small percentage
is inherited, caused by mutations in the genes encoding the proteins that make up the inclusions or
the proteins that increase their production, underscoring the importance of inclusion formation for
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neurodegeneration. These proteins undergo a transformation from a soluble to an insoluble filamentous
state, with a number of intermediates that are considered neurotoxic [3]. However, current knowledge
still does not address the underlying early pathogenic mechanisms; therefore, AD and PD lacks an
effective causal treatment and definitive early diagnostic biomarkers to be used in clinical trials for
drugs discovery. In neurons, tau and αSyn share a significant role in cell trafficking and synaptic
functions and both play a role in regulating mitochondrial homeostasis. Since the peripheral nervous
system (PNS) encompasses axonal and synaptic compartments, where most likely the initial events
in neurodegeneration happen, we aim to review the functional role of tau and αSyn in physiological
conditions and disease, their distribution in PNS, and discuss possible commonalities/diversities as
well as their interaction.
2. The Role of Tau in Physiological Condition in Axons
2.1. Structure of Tau
Human tau is a microtubule binding protein coded by MAPT gene located on chromosome 17
(17q21.31) [4,5]. MAPT primary transcript consists of 16 exons, among which exons 1, 4, 5, 7, 9, 11, 12,
and 13 are constitutively translated; whereas, exons 2, 3, and 10 are alternatively spliced [4]. Alternative
splicing of exons 2 and 3 can include 0, 1, or 2 sequences of 29 amino acids, generating the isoforms 0N,
1N, and 2N respectively. Exon 3 never appears independently from exon 2 [6]. Alternative splicing of
exon 10 can create isoforms containing 3 or 4 carboxy-terminal repeat domains, generating the isoforms
3R or 4R (Figure 1a).
Tau is a ubiquitous protein that is primarily expressed in the nervous system [7], with higher
expression levels in neurons than astrocytes, oligodendrocytes, and Schwann cells [8–10]. In the brain
tau, isoform expression is developmentally regulated: in fetal brain is expressed only the shortest
isoform 0N3R [11], whereas the adult human brain shows all the isoforms [4]. In the adult brain, 0N
and 1N isoforms represent 37 to 54% of total tau, while 2N isoforms are only 9% [12]. 3R and 4R
isoforms are equally represented with few regionally differences: 4R isoform are more expressed in the
globus pallidus, with a temporal frontal cortex distribution [13].
Tau protein can be divided into four domains: the N-terminal, the proline-rich domain, the
microtubule binding region, and the C-terminal. The N-terminal is projected from the microtubule
and interacts with other cellular elements. It can function as a spacer between microtubules
and bridge between microtubules and the cytoskeleton or the plasma membrane, and together
with the neurofilaments, it can determine the caliber of the axons [14]. The proline-rich domain
conveys the link between tau and other proteins such as proto-oncogene tyrosine-protein kinase Fyn
(Fyn) [15] and phospholipase C-γ (PLCγ) isozymes [16], involving tau in signal transduction pathways.
The microtubule binding region allows the interaction between tau and microtubules and is involved
in microtubule assembly, stabilization, and axonal transport. In particular, the tau isoforms 4R show
greater affinity for microtubules compared to 3R tau isoforms [17,18]. Moreover, with the microtubule
binding domain, tau can interact with other proteins such as F-actin [19] and αSyn [20]. Finally, less
is known about C-terminal function [17]; however, this region is essential for the protein to fold and
assume different conformations. Indeed, tau is considered an “intrinsically disordered protein” (IDP)
and does not have a fixed secondary structure, but it is capable of multiple conformations [18,21]. Tau is
highly dynamic in solution, although it features local secondary structure propensities, and an intricate
network of transient long-range contacts related to the complexity of its functions and crucial for
pathogenic aggregation, as demonstrated by nuclear magnetic resonance and cryo-electron microscopy
studies [21,22]. Tau, when free in the cytoplasm, tends to acquire a “paperclip” conformation, in which
N- and C-termini interact with the microtubule-binding repeat regions [18,21]. This conformation is
modulated by post-translational modifications and interactions with microtubules or other proteins.
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Figure 1. Gene, isoforms and functional domains of Tau andαSyn proteins. (a) Schematic representation
of human MAPT gene present on chromosome 17. Its sixteen exons, through alternative splicing of
exons 2, 3, and 10 (green), can generate 6 isoforms. Moreover, in peripheral tissue, the addition of exon
4a (light blue) generates the high molecular weight protein: Big Tau. The protein can be subdivided into
4 functional domains: N-terminal region, Proline rich region, Tubulin binding region, and C-terminal
region. (b) Schematic representation of the SNCA gene present on chromosome 4. Exons 1a and 1b (red)
are not translated. αSyn protein can be subdivided into 3 functional domains: amphipathic region,
hydrophobic non-amyloid component (NAC) domain, and acidic tail.
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2.2. Big Tau in Peripheral Nervous System
In the PNS, tau transcript contains the additional exon 4a, generating the high molecular weight tau,
named “Big tau” [23]. Big tau was described for the first time in 1984 by Drubin et al. [24]. The majority
of the studies on Big tau were performed on mice and rats, whereas human data were obtained mainly
by genomic analysis on transcript alignment [25]. In the PNS, Big tau expression is developmentally
regulated and occurs postnatally [25]. It has been reported in sympathetic neurons [26], in cranial
nerves, dorsal root ganglion (DRG) cells, and sciatic nerve [27,28]. However Big tau has been described
also in neurons of the central nervous system (CNS) that extend axons into the periphery, i.e., in
cerebellum, corpus callosum, and pyramidal tract [28]. Lower molecular weight isoforms are also
expressed in PNS, in particular in sympathetic neurons [26,29], sciatic nerve, and trigeminal nerve [30].
Previous studies in rats suggest that Big tau can also have several variants due to the alternative
incorporation of exon 6 that is never present in low molecular weight tau and leading to the detection
of two isoforms of 110 and 90–95 kDa in the retina and optic nerve, not in DRG cells [28,31].
The incorporation of exon 4a carries the doubling of the N-terminal domain, and allows greater
stabilization and spacing between the microtubules [32]. Long peripheral axons are subject to great
shearing forces and Big tau may increase the structural stability. Moreover, it may contribute to the
high rates of axonal transport observed in peripheral axons, thanks to the greater spacing between
microtubules [33]. Comparing Big tau sequence from Xenopus and mammalian, only 22% of the
exon 4a shows sequence identity compared to 75–83% for the microtubule-binding domain [34]. Plus,
differently from the lower molecular isoforms, the insert has only two phosphorylated sites [25].
These observations suggest that the insertion of exon 4a serves mainly to increase the length of
the N-terminal and not to allow the interaction of the protein with other cellular components [34].
Of interest due to the increased length of the N-terminus, it has been speculated that Big tau may have
less propensity to conformational changes, aggregation, and spreading from neuron to neuron [35,36].
2.3. Tau and Axonal Transport
Although tau was traditionally considered a protein involved only in the regulation of tubulin
polymerization and microtubule stability [37], it is well known that tau can fulfil multiple functions
according to its different cellular locations (Figure 2). In healthy mature neurons, tau is mainly in the
axons bound with the repeat-domain to microtubules, but it is also present in pre- and post-synaptic
structures, in the nucleus, and associated with plasma membrane [38–43].
Along the axon, tau has a non-uniform distribution with a progressive proximal-to-distal increase
concentration and with a higher amount near the growth cone [29]. In the distal axonal portion, tau
promotes microtubule assembly in an unconventional way; indeed tau does not stabilize, but rather
prevents genuine stabilizers, such as the microtubule associated protein 6 (MAP6), from approaching
the microtubule labile domain, allowing the maintenance of a long labile domain and avoiding
a slowdown in axonal growth [44]. The binding between tau and microtubules affects not only
microtubule stability and growth but also influences axonal transport. Tau regulates the molecular
motor proteins dynein and kinesin both directly and indirectly: (1) tau competes with dynein and
kinesin for binding to microtubules, reducing the number of the motor proteins attached and also
the binding frequency [45,46]; (2) tau influences the anterograde and retrograde mobility inducing
the change of direction of dynein and the detaching of kinesin when a patch of tau is present along
the microtubule [47]; (3) tau can activate the protein phosphatase 1 (PP1), which in turn activates
the glycogen synthase kinase 3 beta (GSK3β) that induces the kinesin light chain cargo release [48];
(4) tau can bind to dynactin, favoring the link between dynein and microtubules [49]. Moreover, the
N-terminal domain of tau, even if not directly bound to microtubules but projected away, can regulate
microtubule dynamics, influencing the attachment and spacing between microtubules and other cell
components [32]. The N-terminal works as a spatial separation, preventing microtubule overcrowding
and favoring the transport of vesicles, mitochondria, and RNA along axons [50,51].
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Figure 2. Tau protein in physiology and pathology. On the left, schematic representation of physiological
tau functions at postsynaptic, axonal, and presynaptic level. On the right, pathological effects of
abnormal (oligomeric and neurofibrillary tangles) tau in the three cellular compartments.
Finally, at axonal level, tau can act as a scaffolding protein: tau interacts with kinases
and phosphatases such as PP1 [52], GSK3β [53], cyclin-dependent kinase 5 (Cdk5) [54], and
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Fyn [15], targeting these proteins to microtubules and facilitating their interaction with specific
microtubule-associated protein substrates. Moreover, tau can directly interact with αSyn, which
can modulate the phosphorylation of soluble axonal tau by GSK-3β [20] or by the protein kinase A
(PKA) [55], influencing its link with microtubules.
2.4. Tau and Mitochondria
The presence of tau at the outer mitochondrial membrane and within the inner mitochondrial
space has been recently demonstrated, suggesting that several physiological mitochondria-related
functions may be regulated by tau [56]. Mutated tau inhibits mitochondrial transport toward the
axonal tips, disrupting the energy supply, inducing oxidative stress, and leading to synapses and
axon degeneration. Of interest, the clustering of mitochondria within the cell body induced by tau
overexpression is influenced by tau isoforms; 4R tau has a stronger effect on mitochondrial localization
than 3R isoforms, whereas no differences were observed between 0N, 1N, and 2N isoforms [57].
A direct co-localization between tau oligomers and mitochondria has been reported [58] and this
interaction may increase the precipitation and phosphorylation of the pathological protein and it
may alter mitochondrial quality control, leading to a redox imbalance [59]. Moreover, AD brains
are characterized by mitochondrial fission and fusion dysregulation, shifting toward fission and
resulting in abnormal free radicals’ production [60,61]. Tau accumulation also induces impairment
of mitophagy [62], the physiological process that selectively degrades damaged mitochondria [63].
On the other hand, it has been shown that increased mitochondrial oxidative stress can induce tau
hyper-phosphorylation. Indeed, in a mouse model lacking superoxide dismutase 2 and characterized
by mitochondrial dysfunction and oxidative stress, a striking increase of tau phosphorylation at
different epitopes was observed [64]. Mitochondrial impairment can be observed in AD brain at early
stages and animal models for tau mutations and accumulation report alterations in mitochondrial
function, trafficking [65] and mitophagy [66].
2.5. Tau at the Synaptic Terminals
The exact role of tau at the synaptic terminal is not fully unveiled: it appears to be involved in
neuronal signaling and synaptic plasticity and integrity (Figure 2). These hypotheses arise from the
fact that alterations in the tau protein alone lead to changes in these circuits. Indeed, tau mutation
results in presynaptic bouton density and synaptic vesicle reduction and a decrease of postsynaptic
dendritic spines in the hippocampus [67]. Moreover, tau reduction leads to synapsis’ integrity loss [39].
At the presynaptic level, tau can interact, both directly and indirectly, with proteins involved in
synaptic vesicle dynamics, such as clathrin, dynamin, synaptophysin, synapsin 1, synaptotagmin,
syntaxin-1B, αSyn, and β-synuclein [68,69]. Moreover, through its N-terminal domain, tau can bind to
the synaptogyrin-3 and influence the release of synaptic vesicles [70]. At the postsynaptic level instead,
tau seems to be involved in the regulation of intracellular signaling cascade through the binding with
Fyn, regulating its localization and activity [71,72]. How tau can be present at the postsynaptic level and
therefore in the dendrites is a question that has been tried to answer in recent years. Tau may be directly
translated within dendrites [73], or tau may be released from pre-synaptic terminals and internalized
into post-synaptic regions [74–76]. Finally, tau directly binds actin with the proline-rich domain and
the microtubule binding domain, regulating its dynamics, polymerization, and stability [77,78]. Due to
the crucial role of actin in synaptic remodeling, this interaction can also suggest a role of tau in synaptic
function and, more in general, in the reorganization of the cytoskeleton network.
3. The Role of Alpha Synuclein in Physiological Condition in Axons
3.1. Structure of Alpha Synuclein
αSyn was initially identified in cholinergic vesicles of the Torpedo fish electric organ [79] suggesting
from the beginning a functional role at the presynaptic level. It belongs to the super-family of synucleins,
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evolutionary highly conserved proteins, that also includes β and γ synuclein, sharing a common
amino-terminal sequence, characterized by a different number of repeat regions [80]. αSyn is encoded
by SNCA gene on the long arm of chromosome 4 (q22.1) and is characterized by a 140 amino acid
(aa) sequence including three domains: the N-terminal region (1–60 aa), the non-amyloid component
(NAC) region (61–95 aa), and the C-terminal (96–140 aa) (Figure 1b). The N-terminal region contains
seven conserved repeat regions forming an amphipathic α-helix that is essential for membrane binding,
and is stabilized by high-curvature membrane enriched of phospholipids like synaptic vesicles [81];
this region after acetylation can form α-helical oligomers [82] and of note it contains three sites of
mutations causing familiar PD: A30P, A53T, and E46K [83]. The NAC region contains a hydrophobic
motif that regulates oligomerization and fibril formation and is necessary and sufficient for aggregation
of αSyn [84]. The C-terminus is polar, with the highest proportions of charged residues, and undergoes
phosphorylation at multiple sites suggesting a mechanism of regulation; it is the least conserved
among species and affects membrane binding [85]. In particular, phosphorylation at Ser129, nitration at
Tyr125, Tyr133, and Tyr136 promotes oligomerization, conformational changes, and reduces membrane
affinity [86]. In addition, the C terminal tail mediates αSyn interaction with other proteins [87].
αSyn is considered an IDP due to a high conformational plasticity according to environmental
factors: in physiological condition, in human and rodent CNS, αSyn is an unfolded monomer but it
can acquire a folded conformation or exists as a dynamic oligomer after interaction with other proteins
or biological membranes [83,88].
3.2. Alpha Synuclein at the Synaptic Terminals
αSyn localizes specifically at the axonal terminal [89,90]; it displays a weak association with
synaptic vesicles and is highly mobile at the presynaptic area, explaining its multitasking activity
in cooperation with multiple proteins in regulating the synaptic machinery [85,91]. Of interest, it
has been described that the specific brain region of zebra finch involved in bird song undergo a
significant reduction in αSyn expression during song acquisition, suggesting a role for αSyn in synaptic
plasticity [89].
αSyn and β synuclein are specific inhibitors of phospholipase D2 (PLD2), which generates
phosphatidic acid by hydrolysis of phosphatidylcholine and is localized at plasmatic membranes and
vesicles; thus, synucleins are involved in synaptic membrane biogenesis and vesicle budding [92].
Since it interacts preferentially with small vesicles, αSyn likely regulates the mobility of synaptic
vesicles between the recycling and resting pools [93] (Figure 3). In addition to its ability to bind lipid
membranes, αSyn appears to interact with several proteins at synapsis like synphilin-1, which may
act as an adaptor protein anchoring αSyn to proteins involved in vesicle transport and cytoskeletal
functions [94]. On the surface of synaptic vesicles, αSyn interacts with a family of phosphoproteins
called synapsins: in particular, it binds and cooperates with synapsin III to modulate dopamine
release from nigrostriatal neurons [95] and a recent study shows that synapsin III knock out mice do
not develop αSyn aggregates, nigrostriatal degeneration after overexpression of human wild type
αSyn by adenovirus injection [96]. Moreover, αSyn interact with synaptic vesicle glycoprotein 2C
(SV2C), cysteine string protein α (CSPα), and synaptobrevin/vesicle-associated membrane protein 2
(VAMP2) respectively, for vesicular function and soluble NSF attachment protein receptors (SNARE)
complex assembly and function [97–99]. αSyn cooperates with Rab GTPs, a superfamily of numerous
proteins that regulates axonal transport and synaptic vesicles trafficking; in particular, Rab3 and αSyn
coordinate vesicles tethering at synaptic membranes [100], while Rab5 is involved in regulating the
size of synaptic vesicles [101]. The interaction with Rab4A regulates protein sorting and transport, and
αSyn is sorted to the early endosome by a mechanism dependent on Rab5A and to late endosome by
Rab7 [102]. Interestingly, αSyn overexpression/aggregation can affect Rabs distribution and on the
other hand Rabs dysregulation can influence αSyn pathology and propagation [103].
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Figure 3. αSyn protein in physiology and pathology. On the left, schematic representation of
physiological αSyn functions at the postsynaptic, axonal, and presynaptic level. On the right, the
pathological effects of abnormal (oligomeric and protofibrillary)αSyn in the three cellular compartments.
SERT:serotonin; NET: norepinephrine; DAT: dopamine transporter; VMAT2: vesicular monoamine
transporter 2.
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At synapsis, αSyn also regulates the neurotransmitter release rate, in particular of dopamine by
interacting with vesicular monoamine transporter 2 (VMAT2), which is responsible for dopamine
uptake [104]; and VMAT2 is found in Lewy bodies (LBs) [105]. Moreover, αSyn controls dopamine
transporter (DAT) functions; in fact, in physiological conditions, it binds the C-terminus of DAT,
increasing its levels at the plasma membrane and enhancing the uptake of extracellular dopamine [106].
In analogy, αSyn also controls the transporters of serotonin and norepinephrine [107].
A large number of studies support the hypothesis that synaptic dysfunctions are crucial players
in retrograde degeneration of synucleinopathies [108,109].
The role of αSyn in neurotransmission at the synapses is well recognized, but αSyn also plays
a crucial role in neurotransmitter synthesis, calcium homeostasis, mitochondrial function, and gene
expression [110].
3.3. Alpha Synuclein and Mitochondria
αSyn directly modulates mitochondria by regulating their membrane potential, calcium
homeostasis, cytochrome c release, and ATP production [110]. Despite αSyn lacking a canonical
mitochondrial targeting sequence, the N-terminus domain of αSyn, which is rich in positively
charged residues, mirrors the physical-chemical properties of mitochondrial targeting sequences and
can adopt an α-helical conformation that can drive the anchoring of the protein to mitochondrial
membranes [111,112]. The first N-terminal 32 amino acids have been proven to be fundamental for
mitochondrial localization of the protein [111].
αSyn plays a role in physiological mitochondrial respiration: mice knockout for αSyn display
decreased complex I/III activity, that likely derive from αSyn-mediated alterations of mitochondrial
membrane lipid composition [113]. In fact, human fetal dopaminergic primary neurons exposed to
αSyn gene silencing display an impaired connectivity between complex I and III and αSyn [114].
Finally, αSyn physiologically interacts with adenosine triphosphate (ATP) synthase [115]. In addition,
dynamic processes such as mitochondrial fusion/fission and axonal transport are regulated by αSyn:
in αSyn overexpressing dopaminergic cells, it has been shown that αSyn inhibits fusion and stimulates
fission of mitochondria [116]. Mitochondrial fragmentation induced by overexpression of mutant
αSyn (A53T, A30P, E46K) has been also observed [117]. In addition, the overexpression of αSyn in
sensory neurons of living zebrafish embryos induced the fragmentation of mitochondria, leading to
their swelling within the axon [118]. The mitochondrial pathology also includes mitochondrial DNA
transport: mitochondrial motility was reduced by αSyn expression in SH-SY5Y cells and cultured
neurons derived from human embryonic stem cells [119]. Further, αSyn transgenic mice display
increased mitochondrial oxidative stress and DNA lesions [120].
3.4. Alpha Synuclein and Axonal Transport
Although αSyn is classically placed at synaptic terminals, it is now recognized that it also localizes
at endosomes within axons [121] (Figure 3). It is in fact possible that in healthy neurons, αSyn
selectively associates with phospholipidic membranes of different composition, including not only
synaptic vesicles, but also endosomes and late endosomes [122]. It has been shown that αSyn associates
with various cytoskeletal proteins for the homeostasis of cell structure and protein mobility [123].
αSyn interacts withα andβ subunits of tubulin-promoting microtubules polymerization and enhancing
the growth rate of axons [124]. αSyn co-localizes with dynein, which promotes retrograde transport
and is a large motor complex composed of multiple subunits that require activation by dynactin;
dynein dependent axonal transport is severely impaired without αSyn [125]. αSyn also plays a role for
anterograde transport binding kinesin family member 5A (KIF5A), microtubule-associated protein 2
(MAP2), and tau [126]. αSyn interacts with 14-3-3 proteins [127]: the C-terminal phosphorylated form
interacting with 14-3-3 modulates cytoskeletal and vesicular protein trafficking [128]. Moreover, 14-3-3
can be a αSyn chaperone and reduces its uptake and seeding properties [129]. αSyn also binds actin
and modulates neurite outgrowth [130].
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4. The Role of Tau in Neurodegenerative Diseases
Tauopathies are the most common proteinopathies of the human nervous system and are
characterized by the deposition of abnormal tau protein, such as neurofibrillary tangles (NFTs)
and neuropil threads (NTs) in nervous cells [17]. There are 27 different tauopathies, including AD,
progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), Pick’s disease (PiD), chronic
traumatic encephalopathy (CTE), tangle-only dementia, fronto-temporal dementia with parkinsonism
linked to chromosome 17 (FTDP-17), and argyrophilic grain disease (AGD) [131,132].
Tauopathies typically display at early phases a “dying back” pattern of neurodegeneration, with
dystrophic axons, spheroids, axonal swellings, and evidence of disrupted fast axonal transport [133,134].
Several conformational variants of pathological tau, known as strains that can have dramatically
different seeding and spreading abilities, have been reported [135]. For example, pathological tau
isolated from brains of individuals with progressive supranuclear palsy (PSP) was conformationally
distinct from and had greater seeding ability than pathological tau isolated from brains of individuals
with AD [136].
4.1. Tau Mutations Impair Microtubules Binding Affinity
Abnormal tau protein can be the result of genetic mutations or post-translational modifications.
More than 80 MAPT mutations have been identified; they are mainly missense mutations, which
alter tau sequence, or splicing mutations, which change the expression of the different isoforms.
The majority of missense mutations affect the microtubule-binding domain, reducing tau affinity for
microtubules and increasing tau tendency for aggregation [137,138]. Whereas, the majority of splicing
mutations are within or near intron 10, increasing or reducing its inclusion in the transcript and thus
changing the ratio between the 3R and 4R isoforms [139]. In AD, CTE, and tangle-only dementia,
all six brain tau isoforms (3R and 4R) are present in neuronal cells as NFTs and NTs [17]. Instead in
PSP, CBD, and AGD, only 4R tau isoforms are accumulated, and in PiD, only 3R tau isoforms are
deposited as Pick’s bodies [17]. The 3R/4R imbalance is strictly linked to neurodegeneration and
several mechanisms have been proposed to explain how this disequilibrium can lead to neuronal
damage. 3R and 4R isoforms have a different affinity to microtubule [140], allowing a fine regulation of
axonal transport. An increase in the 4R isoform, which has the strongest affinity to microtubules, lead
to an higher probability of kinesin detachment [47]; whereas, an increase in the 3R isoform enhances
the number of kinesin driving the cargo and the anterograde mobility [141]. The 3R/4R disequilibrium
impacts the transport of cargos throughout neurons, damaging the cell. Moreover, due to the fact
that the distribution and expression of 3R and 4R isoforms are crucial during brain development,
a new hypothesis suggests the existence of a developmental origin of tauopathies. An imbalance in
3R/4R ratio may lead to genomic instability and aneuploidy, which has been observed in cells from
AD patients and in animal models [142–145]. These aneuploidy cells in the adult human brain may
present a higher vulnerability, leading to age-related neuronal degeneration [146].
Regarding the post-translational modifications, tau undergo phosphorylation [147], acetylation [139],
ubiquitination [148], methylation [149], and truncation [139] which regulate its function within the
cell. Also, in this case a dysregulation of these mechanisms can alter tau conformation and induce
the detachment from microtubules. Moreover, only in tauopathies, tau undergoes also glycation,
deamination, isomerization, and nitration [150].
The detachment of tau from the microtubules allows the exposition of two hexapeptide motifs,
located in the second and third microtubule binding repeats, which display a high propensity to
aggregate [21,151]. Tau dimerization occurs through interactions between the hexapeptide motifs of
two different tau monomers [152]. Further, recruitment of tau leads to the formation of oligomers, which
displays a β-structure [153–155]. Three strands forming a β-helix and 5 strands forming 2 antiparallel
β-sheets regions together create a protofilament [156]. Protofilaments are packed symmetrically,
arranged base to base, in paired helical filaments (PHFs) and asymmetrically, back to base, in straight
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filaments (SFs) [17,157]. PHFs and SFs can aggregate and generate NFTs in the neuronal body and NTs
in neuronal process.
In the human brain, tau can be cleaved behind Thr123, generating an N-terminally truncated,
tau124–441 fragment. This fragment displays a stronger affinity for microtubules than full-length tau,
probably because the removal of the negatively charged N-terminal domain increases its binding to the
negative surface of microtubules [158]. Several N-and C-terminally truncated Tau species are observed
in AD and in other tauopathies [139]. It has been shown that truncation of tau could generate tau
fragments with a higher tendency for aggregation, probably owing to the disruption of the paperclip
structure of tau [159].
4.2. Pathological Tau Hampers Axonal Transport
The majority of tau mutations determine a conformational change, the detachment of the protein
from the microtubules, and the possibility of tau to create aggregates (Figure 2). This can lead to both
the loss of tau physiological functions and acquisition of new abilities that can influence the normal
cellular physiology.
The delocalization of abnormal tau from the microtubules to the cytoplasm prevents
the microtubules assembly and stabilization and the formation of an organized cytoskeletal
network [160,161]. The detachment results in microtubule density and axonal caliber alterations [131]
and prevents tau from playing its role as a scaffolding protein. Mislocalized tau and compromised
microtubules induce axonal transport impairment. Abnormal tau inhibits the access of kinesin to
microtubules track and reduces binding frequency and mobility of dynein and kinesin [162]. Moreover,
detached tau exposes the phosphatase-activating domain (PAD), generally sequestered in physiological
tau [163,164], which can activate in a constitutive and unregulated manner the PP1/GSK3β pathway,
inducing a progressive kinesin light chain cargo release [48,165]. Axonal transport disruption means
incorrect transport of proteins, vesicles, mitochondria, and peroxisomes [166]. An incorrect relocation
of the mitochondria in peripheral axon, a decrease in ATP synthesis, glucose and lipid metabolism,
and an increase in oxidative stress lead to progressive dying-back degeneration [167]. Moreover,
abnormal tau can increase intracellular Ca2+ levels by directly inhibiting plasma membrane Ca2+
ATPase [168] and by reducing axonal mitochondria [169]. The increase of Ca2+ in the neuron promotes
the abnormal activation of calcium-activated proteases and the proteolysis of critical cytoskeletal
protein components [170]. At the synaptic level, the increase of Ca2+ caused by abnormal tau leads to
an inhibition of synaptic vesicle exocytosis and synaptic transmission [171]. Moreover, in a mouse
model, it has been observed that oligomeric tau can completely deregulate synaptic activity, inducing
aberrant long-term potentiation/depression [67,172]. Finally, the impossibility of maintaining the
neuronal shape and the loss of contacts with neighboring cells, through synaptic afferents and efferents,
induces synapses deterioration [173].
4.3. Neuroanatomical Stages of Tau Accumulation in Alzheimer’s Disease
In an AD brain, pathological hyperphosphorylated tau aggregates appear first in the axons
of locus coeruleus of the pontine tegmentum nerve cells (subcortical stage 1a) and then in the
somatodendritic compartment (subcortical stage 1b) [174]. The migration from the axon to the
somatodendritic compartment could be caused by defective mechanisms in functionally impaired
axons [175]. Indeed, during AD pathogenesis, hyperphosphorylated tau is free in the cytoplasm of
both axon and somatodendritic area. Over time, hyperphosphorylated tau becomes less soluble and
starts to aggregate and to be confined solely to the somatodendritic compartment, where pre-fibrillar
structures develop [175]. In the axon instead, hyperphosphorylated tau remains for a longer period in
a non-fibrillary state and can be transferred into presynaptic terminals, where they become available
for synaptic transport [176]. From the locus coeruleus, pretangle tau reach the transentorhinal region
of the cerebral cortex, where it is possible to observe the first NFTs [174]. Subsequently, neurofibrillary
lesions spread from the transentorhinal region into the olfactory bulb (NFT stage I); the entorhinal
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region and the hippocampal formation (NFT stage II); basal temporal neocortex (NFT stage III); the
temporal, insular, and frontal neocortex (NFT stage IV). Finally, in the last two stages, NFTs also invade
the neocortical association areas (NFT stage V and VI) [174]. How the pathology moves from an area to
another is still a cause for debate. Several hypothesis have been proposed: (1) locus coeruleus neurons
send aberrant signals to the cortical nerve cells of the transentorhinal region that might induce a
transient overproduction of tau; (2) axonal hyperphosphorylated tau is carried by synaptic vesicles and
conveyed to the transentorhinal neurons post synapsis; (3) tau spread in a “prion-like” manner [174].
In the transentorhinal region, pretangle tau develops to NFT.
Despite the accumulation of abnormal tau being the basis of all tauopathies, these diseases differ
from each other with regard to the brain areas affected, the kind of tau aggregates, and the cell types in
which the aggregates are found, which is either neurons or astrocyte or oligodendrocytes. For example
in PSP, different from AD, pathological tau accumulations start in the neurons of subcortical and
brainstem nuclei, in the oligodendrocytes of the globus pallidus, and in the astrocytes of the striatum,
followed by tau accumulation in cortical astrocytes, neurons, and oligodendrocyte, respectively, with a
fronto-parietal to temporal to occipital sequence [177].
5. The Role of Alpha Synuclein in Neurodegenerative Diseases
αSyn forms misfolded aggregates in a group of neurodegenerative diseases collectively known
as synucleinopathies, including PD, dementia with Lewy bodies (DLB), and multiple system
atrophy (MSA) [178]. PD and DLB are thought to be a spectrum of disorders characterized by
intraneuronal aggregates called LBs and Lewy neurites (LNs), whereas MSA is characterized by
abundant oligodendroglial αSyn aggregates, termed glial cytoplasmic inclusions (GCI), with rare
neuronal inclusions [179].
The central role of αSyn in PD is extensively supported by neuropathological and genetic studies:
the presence of intracellular inclusions such as LBs and LNs that are principally constituted by
aggregated αSyn [180] and the discovery of familial PD caused by mutations in the SNCA gene
(A53T) [181]. Since then, several other point mutations of SNCA (A30P, E46K, H50Q, G51D and A53E)
have been discovered to cause PD and DLB [182–187]. Plus, duplication and triplication of αSyn locus
have been described [188,189], demonstrating a gene dosage effect with earlier onset and faster disease
progression in subjects with triplication compared to those with duplication [188]. Besides SNCA,
more than 20 PD relate genes have been identified, encompassing LRRK2, GBA1, PINK1, PARK7,
and PARK2 [190–192]. Not only sporadic but also genetic PD display accumulation of brain αSyn
inclusions, and genetic mutations are mostly involved in αSyn aggregation or clearance pathways [193].
αSyn inclusions are thought to spread along neuronal connections in a stereotypical pattern in the
nervous system and pathological forms of αSyn propagate in cell culture models and in vivo in a
prion-like manner. Moreover, different conformational polymorphs of αSyn, called strains, exhibit
distinct biochemical, physical, and structural features and this had led to the view that the clinical
heterogeneity observed in synucleinopathies might be due to distinct pathological αSyn strains [194].
5.1. Axonal Transport Dysfunction Caused by Alpha Synuclein Aggregates May Be the Early Event
in Neurodegeneration
There is a large amount of evidence that defects in axonal transport, due to aggregated αSyn, cause
neuronal dysfunction and are associated with the early phase of PD [195]. The nigrostriatal system in
PD shows a “dying-back“ pattern of degeneration, which starts at the axonal terminals and proceeds
centripetally to the soma [196]. This pattern of axonal damage resembles Wallerian degeneration that
has been widely studied for lesions of peripheral nerves and is characterized by early microtubules
fragmentation, growth cone collapse, and axonal retraction [197,198]. Indeed, αSyn oligomers disrupt
axonal integrity in induced pluripotent stem cells derived human neurons by altering the association
with kinesin, which is essential for the axonal transport [126]. Further proteomics analysis of LBs showed
enrichment of dynein, dynactin [199], and tubulin, which seems to potentiate αSyn fibrillation [124].
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Moreover, the principle mutations linked to PD are in genes encoding for proteins related to the
microtubules: leucine rich repeat kinase (LRRK2), parkin, and αSyn. LRRK2 modulates microtubule
acetylation and organization [200] and mutated LRRK2 inhibits axonal transport of mitochondria by
binding preferentially to deacetylated microtubules [201]. PARK2 mutations lead to the production of
abnormal parkin that induces destabilization of microtubules in murine [202] and human dopaminergic
neurons [203]. Concerning αSyn, it is known that it interacts with multiples cytoskeletal proteins
contributing to the homeostasis of cell structure and protein mobility (Figure 3). In fact, αSyn acts as a
microtubule dynamase, which regulates microtubule nucleation and catastrophes at the growth cone,
and αSyn mutations induce tubulin aggregation [204]. The fact that the majority of point mutations in
the SNCA gene map to the putative tubulin-binding site [200] underlines the importance of this pathway
in causing the pathology. Importantly, in genome-wide association studies, one of the genetic regions
most significantly linked to sporadic PD is the haplotype 1 (H1) located on chromosome 17q21, which
associates also to atypical parkinsonisms, i.e., PSP and CBD. The gene that mostly associates with PD in
H1 haplotype is MAPT; the impact of MAPT variants on axonal trafficking is high and further underlines
the crucial role of axonal transport in PD. Indeed, LBs and LNs are preferentially formed in projection
neurons with very long, thin unmyelinated axons [205] that are more susceptible to axonal transport
deficit, energetic/metabolic stress, mitochondrial failure, and lack the trophic support of glial cells,
such as nigrostriatal dopaminergic neurons, cardiac and skin sympathetic neurons, and gastro-enteric
autonomic systems. Indeed, autonomic dysfunction symptoms and cardiac noradrenergic nerves’
impairment, as demonstrated by radio-labeled meta-iodobenzylguanidine (MIBG), are early features
in the course of PD [206]. Moreover, pathological evidence of aggregated αSyn has been demonstrated
in vivo and post-mortem in gastro-intestinal tissue, skin biopsy, and submandibular glands (see the
paragraph “Alpha synuclein in the peripheral nervous system as a biomarker for synucleinopathies”).
In addition, nigrostriatal neurons are characterized by extensive branching that exponentially increases
the number of synapses at each axonal terminal, determining a substantial rise of the expression of
αSyn [207]. The expression level of substrates, amplifying the pathogenic seed, could contribute to
the selected vulnerability of different neuronal populations according to the recent theories on the
misfolded protein transmission in neurodegenerative diseases [208,209].
5.2. Neuroanatomical Stages of Alpha Synuclein Accumulation in Parkinson’s Disease
In PD brain, αSyn aggregates appear first in the olfactory bulb and in the dorsal motor nucleus of
the vagal nerve (DMV) [174,210]. In the viscemotor neurons of DMV, it is possible to observe both
spindle-shaped and globular somatic inclusions, which are respectively LNs and LBs. Whereas, LNs
are prevalently present in the unmyelinated and long axons of the projection cells of DMV in the
medulla [174,210]. In stage 2, retrograde axonal and trans-neuronal transport via descending fibers drive
Lewy pathology from the nucleus of the vagal nerve to the lower raphe nuclei, magnocellular portions
of the reticular formation, and the locus coeruleus [175,210]. During stage 2 and 3, neurons in the
spinal cord, targets of the lower brainstem nuclei projections, develop Lewy pathology. In particular,
neuronal cells of the intermedio-lateral nucleus in layer 7 are affected in stage 2, while the large
nociceptive projection neurons in layer 1 and the motoneurons in layer 9 are affected in stage 3 [174,211].
In stage 3, Lewy pathology also diffuses into the mesencephalic tegmentum and basal portions of the
prosencephalon. At stage 4, LBs and LNs are found in the forebrain, in particular in the transentorhinal
region in the anteromedial temporal lobe. At this point, aggregated αSyn gradually spreads throughout
the entire neocortex: in high-order sensory association areas and prefrontal fields of the neocortex, such
as subgenual, insular and anterior cingulate areas (stage 5) and in the first-order sensory association
areas, primary sensory and premotor/motor fields (stage 6) [175,210].
6. Pathological Tau and the Peripheral Nervous System
Tau pathology preferentially affects neurons with long, scarcely myelinated, axonal projections
in CNS; in fact, in AD subjects, neurons of the neocortex, entorhinal cortex, and hippocampus are
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the most affected [212–215]. Although PNS encompasses neurons with long axons, relying on axonal
transport for energetic-metabolic supply, only a limited number of studies investigate pathological tau
in periphery.
Schwann cells provide mechanical and trophic support to peripheral axons and are essential for
the maintenance of peripheral nerves’ physiological function. It has been reported that tau is expressed
in Schwann cells and is involved in Schwann cells’ mobility and phagocytosis ability; indeed, Yi and
colleagues demonstrate that in MAPT-knockout mice, the decrease of tau expression reduced Schwann
cell migration and suppressed the ability to clear debris after sciatic nerve injury [10]. Thus, tau
pathology can induce neurotoxicity affecting not only neurons, but also damaging Schwann cells and
preventing their trophic and supportive role. Iper-phosphorylated tau has been observed in cutaneous
Schwann cells [216].
6.1. Tau and Autonomic Nervous System
The presence of physiological tau in the myenteric (Auerbach’s) and submucosal (Meissner’s)
plexuses has been demonstrated in axons, cell bodies, and dendrite-like structures [217–220]. In adult
human enteric plexus, mainly two isoforms of tau (1N3R and 0N4R) are expressed [219,221], while the
detection of Big tau is controversial in the literature—some authors were unable to detect it and others
showed a band of approximately 110 kDa by Western blot [219,221]. The presence of phosphorylated
tau has also been investigated. Lionnet et al. demonstrate that tau is phosphorylated at Serine 202,
Threonine 205, Serine 396, and Serine 404 in human colon specimen of both healthy and PSP subjects
and this phosphorylation is resistant to lambda phosphatase treatment [219]. They also observed
C-terminal truncated tau with an antibody specific for tau cleaved at Asparagine 421, but again no
differences were observed between healthy and PSP subjects [219]. In addition to these modifications,
Dugger and colleagues observed phosphorylation at Threonine 231 in AD and healthy subjects [221]
and a threadlike immunoreactivity within the muscularis and ganglion cells of the submucosa and
myenteric plexus of AD patients [217]. NFTs were observed in the celiac, stellatum, and sympathetic
paravertebral ganglia of elderly subjects with or without tauopathies [222,223], suggesting that the
occurrence and frequency of NFTs in the sympathetic ganglia may be related to aging and not to the
presence of brain proteinopathies. In submandibular glands of patients with AD, PSP, and CBD, tau
has been observed phosphorylated at Serine 202, Threonine 205, and Threonine 231 in stromal nerve
fascicles, ganglion cells, and threadlike elements [217].
6.2. Tau and Somatosensory Nervous System
The content and phosphorylation state of tau in the somatosensory fibers, in particular in the
sciatic nerve, has been described during ageing and in AD patients [224]. In the sciatic nerve of elderly
subjects, both Big tau and lower molecular weight isoforms are present. Tau phosphorylation increases
with age. In AD subjects instead, the amount of physiological tau decrease over time, while the
phosphorylation state increases, even though no aggregated tau is observed [224], suggesting that
the increased phosphorylation of tau in peripheral neurons may not necessarily be accompanied by
aggregated formation. However, these studies on PNS are relatively few, with small sample sizes in
each diagnostic group, and may have been confounded by the limited sensitivity and specificity of
reagents available at the time. More recently phosphorylated tau has been described in cervical skin
peripheral nerve terminals of patients with PSP [216].
6.3. Tau and Olfactory Nervous System
Olfactory receptor neurons are bipolar cells present in the epithelial lining of the nose [225].
Their axons project to the olfactory bulb, forming the olfactory nerve that provides information to the
CNS. Physiological tau is present especially in the olfactory nerve and olfactory bulbs, with a lower
expression in the receptor neurons and in axonal bundles of the olfactory epithelium submucosa [226].
Apparently, Big tau is not expressed in the bipolar cells of olfactory ganglia and olfactory nerve [33].
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Olfactory dysfunction is an early and common symptom in several neurodegenerative diseases,
including AD, CBD, frontotemporal dementia, to a lesser extent in PSP, as well as in PD and
synucleinopathies [227]. In AD patients, olfactory symptoms correlate with the early phases [228]
and advancement of the AD pathology [229,230] and olfactory dysfunctions reflect neurodegenerative
disease pathology in the brain [230]. AD olfactory epithelium shows a striking accumulation of
dystrophic neurites [231,232]: abnormal neuronal processes characterized by aberrant sprouting,
dystrophic expansion, and proteins accumulation, among which, physiological and abnormal/aggregate
tau and αSyn [233]. These neuritic abnormalities are not specific and exclusive for AD patients, due
to their presence also in healthy subjects and patients with other neurodegenerative diseases [234].
Nevertheless, in AD olfactory epithelium PHFs pathological lesions are significantly more frequent
and more abundant compared to normal elderly controls or patients with other neurodegenerative
diseases [233]. Abnormal tau was described in dystrophic neurites coursing through the lamina propria
and in the neuron somata with a morphological appearance typical of NFTs [233]. Moreover, these
lesions correlate with higher levels of PHF tau pathology in the cortex of AD subjects [233]. Finally,
NFTs have been observed also in dendrites of the olfactory receptor cells and in nerve bundles [235].
To date, the olfactory mucosa seems to be the peripheral tissue with a major diagnostic utility for AD,
even with some limitations in terms of specificity.
7. Pathological Alpha Synuclein and the Peripheral Nervous System
7.1. Dual Hit Hypothesis
In 2007, Braak proposed the dual-hit hypothesis on the origin of PD. Since αSyn aggregates
appear first in the olfactory bulb and in the DMV, it was postulated that PD possibly originates also
from the PNS gastro-enteric synapses and it invades the CNS via retrograde axonal transport [236].
This hypothesis has been supported by many clinical observations and experimental settings. αSyn can
be detected in the gut of PD patients up to 20 years before the diagnosis [237] and truncal vagotomy
appeared to lower the risk of developing PD of 40–50% after 10–20 years [238]. In a transgenic rat
model with excess levels of αSyn, the injection of αSyn fibrils into the duodenum fully recapitulated
the trans-synaptic propagation through the vagus nerve to DMV, through the sympathetic connectome
to the celiac ganglion and IML, and then rostrally to the brainstem with involvement of locus ceruleus
and substantia nigra. This model also provided the first evidence of a secondary anterograde transport
to the stomach and heart [239].
However, due to the high clinical heterogeneity of PD patients and the fact that a small number of
PD subjects do not present pathology in the DMV, it has been proposed more recently that PD can
be divided in PNS-first and CNS-first types. The PNS-first phenotype is associated with REM sleep
behavior disorder (RBD) during the prodromal phase and displays a marked autonomic damage before
the dopaminergic system involvement, while the CNS-first is RBD negative during the prodromal
phase and presents a marked involvement of the nigrostriatal system before the autonomic PNS
damage [240].
7.2. Alpha Synuclein in the Peripheral Nervous System as a Biomarker for Synucleinopathies
The involvement of PNS, either early or later on in the course of the disease, has been widely
demonstrated in PD and synucleinopathies. In fact, in PD and DLB, αSyn aggregates have been
detected throughout the PNS in sympathetic ganglia, enteric nervous system, cardiac and pelvic
plexus, submandibular glands, adrenal medulla, and skin [241]. In MSA, αSyn aggregates have been
demonstrated in sympathetic ganglia [242], in Schwann cells cytoplasm [243] and in skin autonomic
nerves [244]; of note, a study on sural biopsy showed a reduction of small unmyelinated fibers
(somatosensory and autonomic) in 23% of MSA cases [245] and a mild degeneration of cardiac
sympathetic nerves has been described [206]. These findings have important implications for the
discovery of in vivo biomarkers of disease that are so urgently needed for neurodegenerative diseases.
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A recent systematic review and meta-analysis on determining the most suitable tissue for assessing
αSyn deposits in PD found that skin biopsy using anti-phosphorylated αSyn antibodies displayed
the best diagnostic accuracy, when compared to gastro-intestinal tract, submandibular glands, minor
salivary glands, parotid glands, and olfactory epithelium [246]. Indeed, phosphorylated αSyn has
been found in skin small fibers nerves innervating autonomic structures [247] in PD, and of note also in
RBD patients, suggesting the potential value of skin biopsy as an early biomarker of disease [248,249].
More recently, aggregated αSyn has been demonstrated in skin nerves by conformational antibodies,
recognizing oligomeric forms of the protein [244,250] and by using proximity ligation assay technology
in the skin [251]. In addition, skin biopsy offers the great advantages of being minimally invasive,
compared to other biopsy sites like the gastro-enteric system; it can be repeated in time during
follow-ups and offers the unique opportunity to access the sympathetic structures in the skin (sweat
glands, small arterioles, muscle arrector pili), which animal models have demonstrated as possibly
involved early [239]. Of great interest, skin biopsy can be used to detect small fiber neuropathy.
Several clinical studies have shown that PD patients develop a small fiber neuropathy [252] which
is most likely expression of the neurodegenerative process in itself and seems to correlate to disease
progression [244,253]. These findings imply a possible role of small fiber neuropathy as a biomarker
of disease.
8. Tau and Alpha Synuclein Cross Talking in Causing Neurodegeneration
Among neurodegenerative diseases, pure single proteinopathies are rare: they generally exhibit
associated deposits of other misfolded aggregated proteins. For example, co-occurrence of tau and
αSyn inclusions in brain pathologies is frequent: more than 50% of AD patients show LBs [254], while
tau pathology has been observed in sporadic and genetic PD [255,256]. Moreover, tau and αSyn
co-localization has been described in both LBs and NFTs [257,258], suggesting that the interaction
between tau and αSyn may influence the development and spreading of neurodegeneration. Of note,
genome-wide association studies have shown that genetic variants of MAPT mutations were associated
with both tauopathies and synucleinopathies [259,260], while SNCA mutations were associated with
NFTs’ pathology [261].
Tau and αSyn are present at both axonal and synaptic levels and can physically interact: the
C-terminus of αSyn links the microtubule-binding region of tau [20]. This interaction influences
the binding of tau to microtubules contributing to the regulation of microtubules’ stability and
polymerization. Modifications in these regions may influence their interaction; for example,
phosphorylation of the serine 214 residue of tau was identified to increase αSyn binding [55]. Moreover,
αSyn can influence tau functions, also regulating its phosphorylation by GSK-3β and PKA interaction.
Due to the fact that oxidative stress can stimulate αSyn, in pathological conditions, αSyn may lead
to excessive phosphorylation of tau by GSK-3β [262]. Furthermore, tau and αSyn also promote
each-other’s aggregation in in-vitro experiments: αSyn’s NAC domain can induce tau polymerization
and tau promotes formation of αSyn inclusions [256,263].
It has been shown that αSyn disrupts the actin network, causing dynamin related protein 1 (Drp1)
dependent mitochondrial fission defects [264] and a very similar mechanism underlines tau pathology
in mitochondria [265], implying that αSyn and tau toxicity converge onto a common knot that is f-actin
stabilization and mitochondria damage [266].
Indeed, transgenic mouse models with the co-occurrence of tauopathy and synucleinopathy
display both protein aggregations, cognitive and motor deficits, further suggesting a synergic effect
of the two pathological proteins on neurodegeneration. Indeed, mutant P301L tau rats display a
higher level of αSyn and its phosphorylated form and develop motor dysfunction [267,268] and mice
overexpressing K396I tau show L-Dopa sensitive parkinsonism [269]. In analogy, animal models of
synucleinopathies show cognitive deficit and abnormal tau accumulation, like in the case of mice
overexpressing A53T and E46K αSyn, who display abundant tau accumulation [270,271].
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9. Tau and Alpha Synuclein Commonalities and Diversities
Normal and pathological tau and αSyn share biological and biophysical properties: they have a
high content of charged amino acid residues and are highly soluble in aqueous buffers [272]. Moreover,
they have long half-lives in vivo and as ‘natively unfolded’, they are heat-stable [273]. They also
contain stretches of hydrophobic residues that are involved in forming the core of the assembled
fibrils [274]. Further, both proteins are phosphorylated, and these modifications have been implicated
in facilitating their conversion into fibrils [275]. αSyn and tau fibrils, either assembled in vitro from
recombinant protein or derived from pathological aggregates, share common properties with amyloid:
they form 10–15 nm diameter filaments that are detected by Congo red and Thioflavin S [276,277].
From a functional point of view, tau andαSyn share a significant role in cell trafficking and synaptic
functions at the axonal level and both play a role in regulating mitochondrial homeostasis. In fact,
pathologic αSyn and tau cause mitochondrial dysfunction and oxidative stress, and tau aggregates
amplifies the neurotoxic effects on mitochondria by interacting with αSyn; on the other hand, oxidative
stress caused by mitochondrial impairment induces aggregation of both αSyn and tau [278].
9.1. IDPs and Neurodegenerative Diseases
Similar to most of the proteins involved in neurodegenerative proteinopathies, tau and αSyn
are IDPs [87,279,280]. In fact, tau and αSyn are intrinsically disordered hubs with highly extended
proteomes [281]. IDPs have been shown to have redundant biological functions, including cell
signaling, transcription, translation, and cellular trafficking/ synaptic function [87,279,280]. Indeed,
αSyn displays a high predicted disordered sequence (90%) and an elevated binding promiscuity
with 416 interactors; similarly, tau has 77.6% of predicted disorder and 73 binding partners [281].
IDPs exert their molecular functions using conformational flexibility and heterogeneity and are tightly
regulated by extensive post-translational modifications such as phosphorylation, acetylation, and
glycosylation [281]. The binding selectivity of charged IDPs like αSyn and tau may be also determined
by regulatory mechanisms that are dependent on its subcellular localization, or during relevant stages
of development or cell cycle [83]. These properties at the same time can be responsible for the different
conformational species that these proteins can generate in different cellular milieus, causing different
toxicity and spreading patterns characterizing the multiple clinical and neuropathological phenotypes
of neurodegenerative diseases.
9.2. Aggregation, Propagation, and Prion Concept
Tau and αSyn are soluble proteins showing a propensity to aggregate in insoluble filaments, which
constitute the end point of the aggregation process that is localized intracellularly in neurons and glia
cells, differently from β-amyloid that accumulates in the extracellular space. The process involves the
formation of a pathological seed, a rare and energetically disadvantageous event, which requires high
protein concentration and exposure of amide groups. Pathological seeds induce the rapid assembly of
other soluble protein monomers, and then the subsequent fragmentation generates new seeds with an
acceleration of the process [2]. In analogy to prions, misfolded proteins generate seeds that can guide
the aggregation of further homologous protein and propagate transcellularly. The event is considered
non-cell autonomous and propagate to distant regions of the brain in a stereotypical manner for both
tau and αSyn, predicted by the pathological staging of tauopathies and PD [3].
Of interest, recently developed ultrasensitive technologies based on the aggregation properties of
different pathologic seed of tau and αSyn, like Real Time Quaking Induced Conversion assay (RT-QuIC),
developed in the field of prion diseases, and Protein misfolding cyclic amplification (PMCA), are
promising tools in detecting pathological aggregates in CSF, brain and olfactory mucosa homogenates
for the diagnosis of several synucleinopathies and tauopathies [282–284].
Int. J. Mol. Sci. 2020, 21, 5030 18 of 33
9.3. Pathological Tau and Alpha Synuclein Target Different Neuronal Cells and Display Different
Spreading Patterns
In contrast to tau that is distributed throughout the neuronal cells, αSyn localizes specifically at
the synapses, with relatively low presence in the cell bodies, dendrites, or in extra synaptic locations
along axons [89,90]. In adult neurons, αSyn and tau may interact with each other, when low levels of
αSyn are expressed in the cell body/axon before being transported to synaptic terminals. However, it is
especially under pathological conditions, when impaired axonal transport leads to accumulation of
αSyn along axons and cell bodies, that this interaction becomes more likely [274].
Pathological aggregates of both proteins involve mainly projection neurons, with long and sparsely
myelinated axons, but the pathological cascade starts at different preferential sites according to the
disease, locus coeruleus in AD, and olfactory bulb/DMV in PD; and propagate in a standardized
pattern. Further, AD and tauopathies display pathological protein inclusions that remain confined
mainly inside the CNS, while in PD, they also involve the PNS autonomic and somatosensory nervous
systems [174]. Besides, multiple evidences and experimental studies have demonstrated the αSyn
transmission from the PNS to CNS, while the evidence of tau seeds spreading from the periphery to the
brain is not as strong as for αSyn. Indeed, the apparent minor impact of tauopathies on PNS compared
to synucleinopathies could be due to the less “pathogenic” phenotype of Big tau in peripheral nervous
tissues with a possible minor propensity to misfolding, aggregation, and spreading. More studies on
peripheral Big tau in humans are certainly needed to confirm this hypothesis and to investigate the
intriguing possibility of an “innate” mechanism of neuroprotection exerted by Big tau [25].
10. Conclusions
Synucleinopathies and tauopathies are characterized by the accumulation of misfolded proteins
in selected populations of neurons: whether this pathological accumulation is the cause or the
effect of axonal transport dysfunction is still debated. The identification of familiar forms of disease
caused in the majority of cases by genes encoding for proteins involved in axonal transport and
the evidence of toxic models of disease caused by chemical agents causing axonal transport deficits
and neurodegeneration support the theory that initial axonal transport impairment can trigger
neurodegeneration. Another key player is mitochondrial dysfunction, which is apparently strictly
linked to axonal transport derangement and is a common feature in synucleinopathies and tauopathies,
both defined by a dying-back degeneration pattern. In addition, myelination could have a role, since a
striking susceptibility to misfolded protein pathology is shared by small diameter and unmyelinated
or sparsely myelinated nerve fibers. An explanation could certainly be the lack of trophic support by
myelinating glial cells but it is of interest that myelin and/or myelinating cells also influence the density
of axonal mitochondria, such that unmyelinated axons display a higher density of mitochondria than
myelinated internodes [285,286]. Plus myelin also locally increases axonal calibre by modulating
axonal neurofilament transport [287,288], and phosphorylation/spacing [289].
Another recent and important concept is that tau and αSyn are IDPs generating different
conformational strains, which are likely responsible for the heterogeneity of pathological findings
and clinical phenotypes [209]. Several common routes of pathogenesis underlying IDP-related
diseases and protein misfolding diseases suggest promising potential points of intervention to
prevent neurodegeneration.
In conclusion, more attention to axonal biology can add important clues to the pathogenesis
of neurodegenerative disease and shed light on possible novel neuroprotective pathways. The cell
death paradigm of neurodegeneration will need to be substituted or at least associated with the axonal
degeneration paradigm as an early crucial event in the neurodegenerative pathways causing misfolded
proteins-derived pathologies.
Furtherly, PNS deserves more attention because it encompasses axonal and synaptic compartments,
where the initial events in neurodegeneration most likely happen. In addition, due to the easy
accessibility of PNS tissues, they offer the great opportunity to detect potential novel biomarkers of
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disease that are urgently needed for neurodegenerative conditions. The peripheral nervous tissues
represent an easily accessible window to brain pathology in neurodegenerative diseases.
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Abbreviations
AD Alzheimer’s Disease
PD Parkinson’s Disease
αSyn Alpha Synuclein
PNS Peripheral Nervous System
CNS Central Nervous System
IDP Intrinsically Disordered Proteins
aa amino acid
NAC non-amyloid component
NFTs NeuroFibrillary Tangles
NTs Neuropil Threads
PSP Progressive Sopranuclear Palsy
CBD CorticoBasal Degeneration
PiD Pick’s Disease
CTE Chronic Traumatic Encephalopathy
AGD Argyrophilic Grain Disease
PHFs Paired Helical Filaments
DMV Dorsal Motor Nucleus of the Vagal nerve
DLB Dementia with Lewy Bodies
MSA Multiple System Atrophy
LBs Lewy Bodies
LNs Lewy Neurites
RBD Rem Behavior Disorder
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